Markets witnessed a volatile session on Thursday, eventually ending on a flat note as the index took a breather after the recent rebound. Analysts reiterate positive stance on the Nifty and recommend a buy on dips approach, focusing on stock selection based on rotational sectoral trends.

In today’s trade, shares of Wipro, HUL, Angel One, Alembic Pharma, HDFC Life among others will be in focus due to various news developments and fourth quarter results.

Angel One

Angel One reported a sharp rise in profit for the March quarter, driven by strong client activity and operating leverage. Profit after tax stood at Rs 320 crore in the fourth quarter, marking an 84% year-on-year (YoY) increase, while rising 19% sequentially. The strong profit growth was supported by higher trading volumes and better monetisation across segments.Wipro

IT services major Wipro reported 2% fall in its consolidated net profit at Rs 3502 crore in the fourth quarter. The company’s board has also approved a buyback of Rs 15,000 crore, along with its financial results. Revenue from operations, meanwhile, increased 8% YoY to Rs 24,236 crore.

HDFC Life

HDFC Life Insurance said it will issue shares worth Rs 1,000 crore to promoter HDFC Bank on a preferential basis, even as the insurer reported a modest rise in March quarter profit. The company will allot 1.45 crore equity shares at Rs 688.52 apiece to HDFC Bank, subject to shareholder and regulatory approvals. The capital raise aims to strengthen solvency and support future growth.
HUL
Hindustan Unilever Limited has hiked prices across its soap portfolio, passing on rising raw material and packaging costs to consumers, The Times of India reported, with increases ranging between Rs 1 and Rs 20. For FMCG companies that were counting on GST cuts to revive consumption after a prolonged slowdown, the current situation may push back a demand recovery just as early signs of improvement had begun to reflect in recent quarterly earnings.

Alembic Pharma

Alembic Pharmaceuticals Ltd on Thursday said it has received final approval from the US health regulator for its generic version of methotrexate injection used in treatment of different types of cancers and arthritis.

A senior manager at Bloomberg LP is facing serious allegations after a lawsuit claimed the company’s internal chat system was used to send explicit and unwanted messages to an employee.

The case, filed in New York Supreme Court on April 13, accuses the company of failing to act on repeated complaints.

The lawsuit was brought by Charles Kyle O’Rourke, an account manager who has worked at Bloomberg since 2019.

He claims senior manager Peter Elliot sent him inappropriate sexual messages during work conversations, creating what the complaint describes as a hostile work environment.

According to the filing, the messages were sent in February 2025 while O’Rourke was discussing travel plans.

The complaint alleges Elliot made crude comments involving sex acts and personal behavior that were not welcome.

One message reportedly included explicit language about travel and sexual activity, which O’Rourke says crossed professional boundaries.

“Over the course of his nearly six-year tenure, Mr. O’Rourke has been subjected to repeated acts of sexual harassment,” the complaint states, adding that the situation worsened due to what it describes as a lack of support from management, NY Post reported.

O’Rourke says he reported the messages to senior leaders, but no action was taken. The lawsuit claims the harassment continued despite his complaints, placing responsibility on the company for not stepping in.

Bloomberg Lawsuit Alleges Retaliation

The filing also includes claims of retaliation. O’Rourke alleges that after he raised concerns and asked for workplace accommodations related to ADHD and anxiety, his direct manager, David LaPaglia, began treating him unfairly.

The complaint says LaPaglia micromanaged his work, reduced his client responsibilities, and told clients he was no longer with the company.

According to NationalToday , as a result of the situation, O’Rourke took a medical leave of absence on August 19, which the lawsuit describes as a response to pressure that pushed him toward leaving his job.

The case brings several legal claims against Bloomberg under New York State and City laws.

These include allegations of a hostile work environment, sex discrimination, disability discrimination, and retaliation.

The lawsuit also argues that Bloomberg is responsible for the actions of its managers because of their leadership roles.

O’Rourke is seeking damages and is asking the court to require changes to Bloomberg’s internal policies, including stronger harassment reporting systems and better employee protections.

In response, a spokesperson for Bloomberg said the company has reviewed the claims and believes they have no merit.

Originally published on vcpost.com

Three Los Angeles-area residents were recently convicted in an unusual insurance fraud scheme using a person in a bear costume to fake attacks on high-end vehicles to collect insurance payouts.

As part of the California Department of Insurance’s Operation Bear Claw, Alfiya Zuckerman, 39, of Valley Village; Ruben Tamrazian, 26, of Glendale; and Vahe Muradkhanyan, 32, of Glendale, pleaded no contest to felony insurance fraud and were sentenced to 180 days in jail and two years of supervised probation and were ordered to pay restitution.

A fourth suspect, Ararat Chirkinian, 39, of Glendale, is scheduled to return to court in September for a preliminary hearing.

PERSON IN BEAR COSTUME ATTACKS LUXURY CARS IN INSURANCE SCAM, CALIFORNIA INSURERS SAY

The investigation began after an insurance company flagged a suspicious claim tied to a Jan. 28, 2024, incident in Lake Arrowhead. 

The suspects claimed a bear entered their 2010 Rolls-Royce Ghost and caused interior damage, submitting video footage as evidence.

Detectives later determined the “bear” in the video was a person wearing a bear costume and uncovered two additional fraudulent claims submitted to separate insurance companies involving the same date and location but tied to a 2015 Mercedes G63 AMG and a 2022 Mercedes E350.

VISA REPORT HIGHLIGHTS EMERGING SCAMS TARGETING CONSUMERS AND TRAVELERS

A biologist from the California Department of Fish and Wildlife reviewed the video and concluded the animal shown was “clearly a human in a bear suit,” according to authorities.

Detectives executed a search warrant and recovered the costume from the suspects’ home.

Officials said the total loss to the insurance companies was $141,839, though the names of the businesses were not released.

“What may have looked unbelievable turned out to be exactly that, and now those responsible are being held accountable,” Insurance Commissioner Ricardo Lara wrote in a statement Thursday. “My Department’s investigators uncovered the facts, exposed this scam and helped bring these defendants to justice.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

“Insurance fraud is a serious crime that drives up costs for consumers, and no scheme is too outrageous for us to investigate.”

By Jennifer Nash

Originally published on April 15, 2026

The NFIB Small Business Optimism Index fell 3.0 points to 95.8, dropping below the index’s historical average for the first time since April 2025. This was below

David Ferrera is a medical device engineer, entrepreneur, and inventor with nearly 30 years of experience in neurovascular and interventional medicine.

Based in Lake Forest, California, he has built a career focused on turning clinical ideas into real products that improve patient care.

He began his career at Boston Scientific before moving into more specialised roles in vascular and neurovascular technology. Over time, he co-founded and led several companies, including Micrus Endovascular, MindFrame, and Blockade Medical. Each company focused on solving specific problems in stroke treatment and interventional procedures. These ventures were later acquired by major industry players such as Johnson & Johnson, Terumo, Covidien, and Balt.

Ferrera is now CEO of RC Medical, a venture studio that partners with physicians to develop and commercialise new medical devices. He is also CEO and Chairman of Sonorous Neuro. His work centres on building structured, milestone-driven companies that address real clinical needs.

He holds more than 80 U.S. and international patents and is the author of Innovation in Translation, published by Advantage-Forbes. His approach is grounded in discipline, clear problem definition, and practical execution.

Beyond his professional work, Ferrera has been active in philanthropy, serving as Chair of the American Heart Association’s Orange County Heart & Stroke Ball. His career reflects a consistent focus on building solutions that move from concept to clinical use.

David Ferrera on Building What Actually Works in MedTech

Q: How did your career in medical devices begin?

I started at Boston Scientific in the early 1990s. I had a background in plastics engineering, so I was drawn to how materials and design could solve medical problems. Early on, I realised that the field moves quickly, but only when products actually work in real procedures.

Q: What was your first major step into leadership?

Co-founding Micrus Endovascular was a turning point. We were focused on neurovascular devices. At that time, the space was still developing. We had to build technology while also proving clinical value. That company was later acquired by Johnson & Johnson, which gave me a clear view of how larger organisations evaluate products.

Q: What did you learn from your time at MindFrame?

At MindFrame, I led product development and clinical research. We worked on one of the early mechanical thrombectomy systems for stroke. I remember watching cases where time was critical. Every delay mattered. That shaped how I think about design. A device is not just about function. It is about workflow.

Q: You have been part of several acquisitions. How did that shape your approach?

Each acquisition reinforced the same lesson. You need structure from the start. Regulatory planning, manufacturing, and clinical data cannot be afterthoughts. If those pieces are not aligned early, the company struggles later.

Q: Why did you decide to build RC Medical as a venture studio?

After building individual companies, I wanted a more repeatable model. At RC Medical, we partner with physicians who see problems every day. We validate early. We build in stages. We keep teams lean. It allows us to work on multiple ideas while maintaining discipline.

Q: How do physician partnerships influence your work?

They are essential. Physicians understand where procedures break down. One doctor once showed me a case where a device required multiple exchanges. It added several minutes. That insight led to a redesign focused on reducing steps. That is where real innovation comes from.

Q: What role does Sonorous Neuro play in your current work?

Sonorous Neuro is one of the companies formed through this model. I serve as CEO and Chairman. The focus is neurovascular care. We are working on improving how procedures are performed, especially in stroke intervention. It is about precision and efficiency.

Q: What challenges have you seen in recent years?

Regulatory expectations have increased. Capital is more selective. You cannot rely on momentum alone. You need clear milestones and strong data. That has made discipline even more important.

Q: How do you stay close to what matters in the field?

I spend time with physicians. I review clinical data. I focus on what is happening in procedure rooms, not just what is being presented at conferences. Real feedback comes from real use.

Q: How has your leadership style changed over time?

Early on, I focused heavily on technical details. Over time, I shifted towards alignment. Clear goals. Clear accountability. Teams perform better when expectations are simple and direct.

Q: What advice would you give to someone entering this space?

Start with the problem, not the technology. Spend time understanding the clinical need. Then build with discipline. Big ideas are common. Turning them into products that work is the hard part.

NEW YORK — Alphabet Inc. Class C shares traded modestly lower in early morning action Thursday, slipping about 0.15 percent to around $333.97 as Wall Street digested recent gains and prepared for the tech giant’s first-quarter 2026 earnings report later this month amid a record capital expenditure plan focused on artificial intelligence infrastructure.

The stock opened near recent levels after closing Wednesday at approximately $334.47, reflecting a quiet start to trading with volume building steadily. Alphabet has shown resilience in 2026, climbing roughly 6-7 percent year-to-date despite broader market swings tied to geopolitical tensions and elevated AI investment costs across the sector.

With the Q1 earnings call scheduled for April 29, analysts expect another solid beat on revenue and profit, driven by robust Google Search advertising, YouTube growth and accelerating contributions from Google Cloud. Consensus estimates point to earnings per share around $2.62 to $2.63, with revenue projected to continue its steady expansion.

The standout theme for 2026 remains Alphabet’s aggressive bet on AI. The company guided for capital expenditures between $175 billion and $185 billion this year — nearly double 2025 levels — to fund data centers, custom TPUs, networking gear and servers needed to power its expanding AI models and cloud offerings. This massive outlay has sparked debate: some view it as a necessary masterstroke to maintain leadership against rivals like Microsoft and OpenAI, while others worry about near-term margin pressure and the risk of negative free cash flow if returns on the spending lag.

Chief Financial Officer Ruth Porat and CEO Sundar Pichai have emphasized that the investments position Alphabet for long-term dominance in generative AI, cloud computing and enterprise solutions. Google Cloud has posted accelerating growth in recent quarters, benefiting from demand for AI training and inference capabilities. Yet the sheer scale of spending has unsettled some investors, contributing to periods of volatility even as core advertising revenue remains highly profitable.

Antitrust matters continue to loom in the background. A favorable ruling in the U.S. search monopoly case provided relief earlier in the year, allowing the stock to rally toward all-time highs near $350 in February. However, ongoing remedy discussions, potential appeals and separate European Union probes — including scrutiny of the Play Store and AI training data practices — keep regulatory risk on the radar. A large EU fine could materialize in 2026 if compliance issues persist, though Alphabet has historically navigated such challenges while maintaining strong financial performance.

Search advertising, which still accounts for the bulk of revenue, faces evolving competition from AI-powered chat interfaces and changing user habits. Google has integrated Gemini deeply across its products, aiming to defend its dominant position while monetizing AI features. YouTube continues as a growth engine, with Shorts and premium subscriptions driving engagement and revenue diversification.

Waymo, Alphabet’s autonomous vehicle unit, represents another high-potential area. The robotaxi service has expanded in select cities, generating increasing buzz as a future revenue contributor, though it remains in the investment phase with meaningful profits still years away.

Other bets under the “Other Bets” segment, including moonshot projects in health, energy and robotics, continue to consume capital but offer asymmetric upside if any achieve commercial success.

Analysts remain generally constructive on Alphabet despite the heavy AI spending. Several firms have raised price targets following recent earnings beats and the antitrust clarity, with some highlighting the stock’s reasonable valuation relative to growth prospects. The shares trade at a forward multiple that many consider attractive compared to pure-play AI names experiencing higher volatility.

Retail and institutional interest stays elevated. The stock’s inclusion in major indexes and its role as a core holding in tech-heavy portfolios ensure steady attention. Recent sessions have shown Alphabet holding support levels even as broader tech sentiment fluctuates with news from the Middle East conflict and oil price movements.

Thursday’s minor dip appears driven more by profit-taking after a positive Wednesday session than by any fundamental shift. Broader market conditions, with the Dow Jones Industrial Average trading near 48,592 on ceasefire hopes, have supported risk assets overall, providing a favorable backdrop for large-cap tech names like Alphabet.

As investors look toward the April 29 report, key metrics to watch include Google Cloud revenue growth rate, advertising pricing trends, operating margins after increased AI-related costs and any updated commentary on capex allocation or AI product monetization timelines.

The company exited 2025 with strong momentum, posting record quarterly revenue in Q4. Analysts project continued top-line expansion in 2026, though the heavy investment phase could weigh on profitability metrics in the near term. Free cash flow dynamics will draw particular scrutiny given the scale of infrastructure buildout.

Alphabet’s balance sheet remains fortress-like, with substantial cash reserves providing flexibility for acquisitions, share repurchases or further R&D. The company has consistently returned capital to shareholders through buybacks while funding ambitious growth initiatives.

For long-term investors, the narrative centers on Alphabet’s ability to translate massive AI spending into sustainable competitive advantages and higher-margin revenue streams. Success in cloud, autonomous mobility and AI-enhanced search could drive significant value creation over the coming decade.

Short-term traders, meanwhile, are navigating the stock’s sensitivity to quarterly guidance, regulatory headlines and shifts in AI hype cycles. The shares have experienced swings throughout 2026 but have generally trended higher on the strength of core operations.

As trading progressed Thursday morning, GOOG held near the $334 level with limited downside pressure. The session offered little new catalyst, leaving focus squarely on the upcoming earnings cycle and any incremental news around AI advancements or antitrust developments.

Alphabet’s story in 2026 exemplifies the tension facing big tech: balancing enormous upfront investments in transformative technology against the need to deliver consistent shareholder returns. With a market capitalization still among the world’s largest, even modest percentage moves translate into billions in value.

Whether the current capex surge proves prescient or overly aggressive will likely define investor sentiment through the remainder of the year. For now, the stock’s modest pullback appears contained, reflecting healthy digestion rather than concern.

With Q1 results just two weeks away, Alphabet enters a critical period where execution on AI initiatives and clarity on spending returns could set the tone for the rest of 2026.